Expression of epidermal growth factor receptor (EGFR) and Ki67 in feline oral squamous cell carcinomas (FOSCC)

Veterinary and Comparative Oncology

Volumn 9, Issue 2, 2011, Pages 106-117

  Bergkvist, G T ^a   Argyle, D J ^a   Morrison, L ^a   Macintyre, N ^a   Hayes, A ^b   Yool, D A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ANIMAL HEALTH TRUST   (United Kingdom)

Author keywords

EGFR; Feline; Ki67; Prognosis; Squamous cell carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; TUMOR MARKER;

ANIMAL; ANIMAL DISEASE; ARTICLE; CAT; CAT DISEASE; FEMALE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MORTALITY; MOUTH TUMOR; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CAT DISEASES; CATS; FEMALE; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MOUTH NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

FELIDAE;

EID: 79955986559     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2010.00239.x     Document Type: Article

References (55)

1. Stebbins KE, Morse CC and Goldschmidt MH. Feline oral neoplasia: a ten-year survey. Veterinary Pathology 1989; 26: 121-128.
2. Kapatkin AS, Maretta SM, Patnaik AK, Burk RL and Matus RE. Mandibular swelling in cats: prospective study of 24 cats. Journal of the American Animal Hospital Association 1991; 27: 575-580.
3. Dhaliwal RS and Kufuor-Mensah E. Metastatic squamous cell carcinoma in a cat. Journal of Feline Medicine and Surgery 2007; 9: 61-66.
4. Hayes AM, Adams VJ, Scase TJ and Murphy S. Survival of 54 cats with oral squamous cell carcinoma in United Kingdom general practice. Journal of Small Animal Practice 2007; 48: 394-399.
5. Dobrossy L. Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Reviews 2005; 24: 9-17.
6. Reuter CW, Morgan MA and Eckardt A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. British Journal of Cancer 2007; 96: 408-416.
7. Bertone ER, Snyder LA and Moore AS. Environmental and lifestyle risk factors for oral squamous cell carcinoma in domestic cats. Journal of Veterinary Internal Medicine 2003; 17: 557-562.
8. MacEwen EG. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Reviews 1990; 9: 125-136.
9. Kalyankrishna S and Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. Journal of Clinical Oncology 2006; 24: 2666-2672.
10. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW and Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Experimental Cell Research 2003; 284: 31-53.
11. Li C, Iida M, Dunn EF, Ghia AJ and Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009; 28: 3801-3813.
12. Chaturvedi D, Gao X, Cohen MS, Taunton J and Patel TB. Rapamycin induces transactivation of the EGFR and increases cell survival. Oncogene 2009; 28: 1187-1196.
13. Rogers SJ, Harrington KJ, Rhys-Evans P, O-Charoenrat P and Eccles SA. Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Reviews 2005; 24: 47-69.
14. Grandis JR and Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Research 1993; 53: 3579-3584.
15. Mrhalova M, Plzak J, Betka J and Kodet R. Epidermal growth factor receptor - its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas. Neoplasma 2005; 52: 338-343.
16. Bankfalvi A, Krassort M, Vegh A, Felszeghy E and Piffko J. Deranged expression of the E-cadherin/β-catenin complex and the epidermal growth factor receptor in the clinical evolution and progression of oral squamous cell carcinomas. Journal of Oral Pathology & Medicine 2002; 31: 450-457.
17. Hitt R, Ciruelos E, Amador ML, Benito A, Sanchez JJ, Ballestin C and Cortes-Funes H. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. European Journal of Cancer 2005; 41: 453-460.
18. Ma BBY, Poon TCW, To KF, Zee B, Mo FKF, Chan CML, Ho S, Teo PML, Johnson PJ and Chan ATC. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma - a prospective study. Head & Neck 2003; 25: 864-872.
19. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, Machtay M, Rosenthal DI, Bakanauskas VJ, Cerniglia GJ, Bernhard EJ, Weber RS and Muschel RJ. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clinical Cancer Research 2002; 8: 885-892.
20. Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. Journal of Clinical Oncology 2005; 23: 5560-5567.
21. Eriksen JG, Steiniche T, Askaa J, Alsner J and Overgaard J. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. International Journal of Radiation Oncology, Biology, Physics 2004; 58: 561-566.
22. Partridge M, Gaballah K and Huang X. Molecular markers for diagnosis and prognosis. Cancer Metastasis Reviews 2005; 24: 71-85.
23. Brown DC and Gatter KC. Ki67 protein: the immaculate deception? Histopathology 2002; 40: 2-11.
24. Melzer K, Guscetti F, Rohrer Bley C, Sumova A, Roos M and Kaser-Hotz B. Ki67 reactivity in nasal and periocular squamous cell carcinomas in cats treated with electron beam radiation therapy. Journal of Veterinary Internal Medicine 2006; 20: 676-681.
25. Looper JS, Malarkey DE, Ruslander D, Proulx D and Thrall DE. Epidermal growth factor receptor expression in feline oral squamous cell carcinomas. Veterinary and Comparative Oncology 2006; 4: 33-40.
26. Bregazzi VS, LaRue SM, Powers BE, Fettman MJ, Ogilvie GK and Withrow SJ. Response of feline oral squamous cell carcinoma to palliative radiation therapy. Veterinary Radiology & Ultrasound 2001; 42: 77-79.
27. Fidel JL, Sellon RK, Houston RK and Wheeler BA. A nine-day accelerated radiation protocol for feline squamous cell carcinoma. Veterinary Radiology & Ultrasound 2007; 48: 482-485.
28. Postorino-Reeves NC, Turrel JM and Withrow SJ. Oral squamous cell carcinoma in the cat. Journal of the American Animal Hospital Association 1993; 29: 438-441.
29. pfma.org.uk. Pet Population Figures 2010 (2010) [accessed 21 May 2010].
30. Gardner DG. Spontaneous squamous cell carcinomas of the oral region in domestic animals: a review and consideration of their relevance to human research. Oral Diseases 1996; 2: 148-154.
31. cancerresearchuk.org. UK oral cancer incidence statistics (2005) [accessed 08 July 2009].
32. Dorn CR and Priester WA. Epidemiologic analysis of oral and pharyngeal cancer in dogs, cats, horses, and cattle. Journal of the American Veterinary Medical Association 1976; 169: 1202-1206.
33. Evans SM, LaCreta F, Helfand S, VanWinkle T, Curran WJ Jr, Brown DQ and Hanks G. Technique, pharmacokinetics, toxicity, and efficacy of intratumoral etanidazole and radiotherapy for treatment of spontaneous feline oral squamous cell carcinoma. International Journal of Radiation Oncology, Biology, Physics 1991; 20: 703-708.
34. Hutson CA, Willauer CC, Walder EJ, Stone JL and Klein MK. Treatment of mandibular squamous cell carcinoma in cats by use of mandibulectomy and radiotherapy: seven cases (1987-1989). Journal of the American Veterinary Medical Association 1992; 201: 777-781.
35. Hosgood G and Scholl DT. The effects of different methods of accounting for observations from euthanized animals in survival analysis. Preventive Veterinary Medicine 2001; 48: 143-154.
36. Johnson MS, Martin M, Binns S and Day MJ. A retrospective study of clinical findings, treatment and outcome in 143 dogs with pericardial effusion. Journal of Small Animal Practice 2004; 45: 546-552.
37. Northrup NC, Selting KA, Rassnick KM, Kristal O, O'Brien MG, Dank G, Dhaliwal RS, Jagannatha S, Cornell KK and Gieger TL. Outcomes of cats with oral tumors treated with mandibulectomy: 42 cases. Journal of the American Animal Hospital Association 2006; 42: 350-360.
38. Rittà M, Andrea MD, Mondini M, Mazibrada J, Giordano C, Pecorari G, Garzaro M, Landolfo V, Schena M, Chiusa L and Landolfo S. Cell cycle and viral and immunologic profiles of head and neck squamous cell carcinoma as predictable variables of tumor progression. Head & Neck 2009; 31: 318-327.
39. Castagnaro M, De Maria R, Bozzetta E, Ru G, Casalone C, Biolatti B and Caramelli M. Ki-67 index as indicator of the post-surgical prognosis in feline mammary carcinomas. Research in Veterinary Science 1998; 65: 223-226.
40. Eckstein C, Guscetti F, Roos M, Mulas JMdl, Kaser-Hotz B and Bley CR. A retrospective analysis of radiation therapy for the treatment of feline vaccine-associated sarcoma. Veterinary and Comparative Oncology 2009; 7:54-68.
41. nd edn., Oxford, UK, Blackwell Publishing Ltd., 2006: 204-209.
42. Quon H, Liu FF and Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head & Neck 2001; 23: 147-159.
43. Lörz M, Meyer-Breiting E and Bettinger R. Proliferating cell nuclear antigen counts as markers of cell proliferation in head and neck cancer. European Archives Otorhinolaryngology 1994; 251: 91-94.
44. Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S and Di Fiore PP. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Developmental Cell 2008; 15: 209-219.
45. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ and Yarden Y. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. The EMBO Journal 1998; 17: 3385-3397.
46. Olayioye MA, Neve RM, Lane HA and Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. The EMBO Journal 2000; 19: 3159-3167.
47. Wiley HS. Trafficking of the ErbB receptors and its influence on signaling. Experimental Cell Research 2003; 284: 78-88.
48. Damjanov I, Mildner B and Knowles BB. Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues. Laboratory Investigation 1986; 55: 588-592.
49. Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, dos Reis PP, Ho J, Pond GR, Chen H, Chen S, Shyr Y, Winquist E, Soulieres D, Chen EX, Squire JA, Marrano P, Kamel-Reid S, Dancey J, Siu LL and Tsao MS. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. Journal of Clinical Oncology 2007; 25: 2184-2190.
50. Grandis JR, Melhem MF, Barnes EL and Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78: 1284-1292.
51. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT and Harari PM. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008; 27: 3944-3956.
52. Kumar B, Cordell KG, Lee JS, Prince ME, Tran HH, Wolf GT, Urba SG, Worden FP, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JMG, D'Silva NJ, Yang K, Kurnit DM, Bradford CR and Carey TE. Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. International Journal of Radiation Oncology, Biology, Physics 2007; 69(Suppl. 1): S109-S11.
53. Dei Tos AP and Ellis I. Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? European Journal of Cancer 2005; 41: 1383-1392.
54. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascón P, Amellal N, Harstrick A and Eckardt A. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. Journal of Clinical Oncology 2005; 23: 5568-5577.
55. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK and Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. The New England Journal of Medicine2006; 354: 567-578.